Disclosures for "Phase 1b Safety and Preliminary Efficacy of Bilateral Intraputaminal Delivery of AAV2 GDNF (AB-1005) in Participants With Mild or Moderate Parkinson’s Disease"
-
Dr. Van Laar has received personal compensation for serving as an employee of Asklepios Biopharmaceutical. The institution of an immediate family member of Dr. Van Laar has received research support from NIH.
-
The institution of Dr. Christine has received research support from Voyager Therapeutics. The institution of Dr. Christine has received research support from Brain Neurotherapy Bio, Inc. The institution of Dr. Christine has received research support from Michael J Fox Foundation for Parkinson's Research. The institution of Dr. Christine has received research support from Neuraly.
-
Dr. Merola has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Merola has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott. Dr. Merola has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology.
-
-
Bradley Elder has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Bradley Elder has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Icad.
-
Paul Larson has received personal compensation in the range of $0-$499 for serving as a Consultant for Aspen Neuroscience. Paul Larson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Galvani Bioelectronics. Paul Larson has received personal compensation in the range of $0-$499 for serving as a Consultant for Huntington Study Group. Paul Larson has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AiM Medical Robotics. Paul Larson has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Axovant. The institution of Paul Larson has received research support from Voyager Therapeutics. The institution of Paul Larson has received research support from uniQure. The institution of Paul Larson has received research support from Brain Neurotherapy Bio.
-
-
-
-
Prof. Bankiewicz has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for AskBio. Prof. Bankiewicz has stock in Aviado. The institution of Prof. Bankiewicz has received research support from NIH. Prof. Bankiewicz has received intellectual property interests from a discovery or technology relating to health care.